Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

hat we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2007 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC Communications Corp.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Nventa Biopharmaceuticals Corp

Condensed Consolidated Statement of Operations

(Unaudited)

(Canadian dollars)(In thousands, except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaborative research

and development revenue $156 $156 $621 $621

Operating expenses:

Research and development 1,549 1,587 6,596 7,351

Selling, general and

administrative 922 714 4,529 3,565

Corporate restructuring 30 - 844 -

2,501 2,301 11,969 1
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Scientists at NYU Langone Medical Center have ... of the process for turning adult cells into so-called ... vitamin C. Using the new technique in mice, the ... adult skin cells by more than 20-fold compared with ... and reliable, and thus should generally accelerate research aimed ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2
... New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge -- OXFORD, England, October 21, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed ...
... ACCESS PHARMACEUTICALS, INC. (OTC ... leveraging its proprietary drug-delivery platforms to develop treatments in ... it has submitted additional patent applications, covering its Cobalamin-mediated ... injectable drugs, as a result of the growing interest ...
... HONG KONG, Oct. 20 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
Cached Biology Technology:A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 2A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 3A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 4A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 5A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 6A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 7A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 8A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge 9Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 2China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 3China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 4China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 5China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 6China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 7China Cord Blood Corporation Files Its Annual Report on Form 20-F/A 8
(Date:9/19/2014)... professor will study multifunctional and specialized spinal cord ... National Science Foundation grant in the amount of ... professor in the Department of Biology, OU College ... differences between the multifunctional and specialized spinal cord ... and what connections they make. Berkowitz will ...
(Date:9/18/2014)... - Washington State University researchers have developed a unique ... power waste cleanup in rural areas. , The ... an inexpensive and quick way to clean up waste ... while reducing pollution. , Professor Haluk Beyenal and ... Engineering and Architecture discuss the system in the online ...
(Date:9/18/2014)... A novel robotic system that can operate inside the ... as part of a biomedical research partnership program at ... of determining if the robot, in conjunction with real-time ... accurate, less costly, and less discomforting for the patient. ... prostate cancer therapies with greater precision. , Developed by ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... resources at the U.S. Department of Energy,s (DOE) ... how proteins misfold to create the tissue-damaging structures ... called amyloid fibrils, are also implicated in neurodegenerative ... prion diseases like Creutzfeldt-Jacob and mad cow disease., ...
... to KATC Channel 3 in Lafayette, LA on December 17, ... around Acadiana (the mostly French region of Louisiana in the ... instead controlled-sugar cane burns. But some residents living near the ... comfort. From a distance, these fires look like an ...
... trichopoda , a sprawling shrub that grows on just a ... plant in its family and genus. It is also one ... about 200 million years ago. Now, researchers from Indiana University, ... JGI), Penn State University, and the Institute of Research for ...
Cached Biology News:A wrong molecular turn leads down the path to Type 2 diabetes 2A wrong molecular turn leads down the path to Type 2 diabetes 3A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
... The MX80 Series of positioning slides ... motor, ballscrew, leadscrew, micrometer, and manual. ... high performance, cost-effective multi-axis systems. These ... bearings, encoder resolutions down to 10 ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Biology Products: